If Lumen Bioscience achieves its goals, patients will be able to take its drugs the same way some people supplement breakfast: a spoonful heaped onto a bowl of cereal or mixed into juice. The startup harnesses spirulina, protein-rich cyanobacteria touted by many health enthusiasts as a “superfood.”
Lumen CEO Brian Finrow (pictured above, right) acknowledges spirulina’s health benefits, but that’s not why his company embraces it. Seattle-based Lumen turns spirulina into tiny factories that churn out therapeutic antibodies. Finrow says the Lumen technology overcomes many of the challenges of working with cyanobacteria. Research has yielded a crop of gastrointestinal disorder drug… Read more »
UNDERWRITERS AND PARTNERS
